Tip os
Log ind
baby.fødsel.Markus Knigge.jpg
Foto: Markus Knigge / Stock.Xchng

Azanta completes turnaround and turns deficit to profit

Top picks in English:

After a million dollar deficit in 2015, the biotech company Azanta ended 2016 with a positive annual result. There are high expectations to the company’s first drug – the birth pill Angusta.


BY SØREN DURAN DUUS
Offentliggjort 17.05.17 kl. 23:22

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Lundbeck Foundation company goes public

COLOURBOX574526.jpg Top picks in English:

Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.

Goodbye to Novo A/S

Top picks in English:

In order to avoid confusion, Novo A/S, the holding company of Novo Nordisk and Novozymes and one of Denmark’s major life science investors, has decided to change its name.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Novo chief: ”This is data the world has never seen before”

Top picks in English:

Strong phase II data from Novo Nordisk’s pipeline-hope semaglutide gives cause for optimism for chief science officer Mads Krogsgaard Thomsen, who believes Novo holds a new generation of obesity medicine.

Kåre Schultz joins the board of prominent fund

Top picks in English:

CEO in Lundbeck, Kåre Schultz, can add one more board membership to his CV. This time, he enters the board of a prominent Danish fund.

Swedish company fails in study of diabetes vaccine

Top picks in English:

In a study with children at risk of developing type 1 diabetes, an experimental vaccine from Sweden's Diamyd Medical has failed to show a significant difference from placebo. The result cut off more than 20 percent of the company’s share price in just two days.

Forsiden lige nu

Biotelselskab og KU-spinout i ambitiøst vaccinesamarbejde

vaccine.jpg Medicinal & Biotek:

Biotekselskabet ExpreS2ion Biotechnologies er gået sammen med et spinout fra Københavns Universitet om at videreudvikle en teknologi, der kan føre til billigere og langt mere effektive vacciner mod en hvilken som helst sygdom.

Genmab-chefer hiver kæmpegevinst hjem

Medicinal & Biotek:

De to øverste chefer i Genmab har afhændet en betydelig andel aktier i selskabet og til sammen scoret en gevinst på et trecifret millionbeløb.

Tilsyn advarede mod problematisk Seed-option i 2014

Sygdom & Sundhed:

Rapport pegede på kritisable forhold vedrørende købsoptioner i Pre-Seed Innovation for tre år siden. Venstre kræver undersøgelse af forholdene.

Fonde fik adgang til rabat på startups gennem statslige lån

Sygdom & Sundhed:

Private fonde har i flere tilfælde indgået aftaler med lovende opstartsvirksomheder, der kunne gøre fondene til medejere på fordelagtige vilkår.

Tre medicovirksomheder kæmper om Scion DTU’s iværksætterpris

Medicinal & Biotek:

Der er tre virksomheder fra life science-segmentet med, når Scion DTU’s og Industriens Fond for fjerde går i træk blænder op for sin iværksætterkonkurrence Danish Tech Challenge.

Nordea: Bavarian-vaccine har 30 pct chance for lancering

Medicinal & Biotek:

Det er spændende data, som Bavarian Nordic har fremlagt for sin vaccine mod luftvejsvirussen RSV, mener Nordea-analytiker Michael Novod. På baggrund af studiet, vurderer han, at der er 30 pct. sandsynlighed for, at vaccinen kommer på markedet i 2023.

ANNONCE
ANNONCE


ANNONCE